Taiho “Primed And Ready To Go” With Colon Cancer Drug Lonsurf
This article was originally published in The Pink Sheet Daily
Executive Summary
After fast approval of oral chemotherapy combination Lonsurf for late-line colon cancer, U.S. oncology newcomer and Otsuka Holdings subsidiary plans to launch within two weeks at a reasonable price, says CEO Eric Benn.
You may also be interested in...
Taiho Oncology CEO Tim Whitten: Building Upon Lonsurf, Inqovi
Solid tumor-focused Taiho Oncology teams with hematological cancer specialist Astex under the Otsuka umbrella. Taiho also performs US/Canada commercialization for all three firms.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.